# Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis

> **NCT00128895** · PHASE4 · TERMINATED · sponsor: **University Medical Center Groningen** · enrollment: 131 (actual)

## Conditions studied

- Vasculitis

## Interventions

- **DRUG:** azathioprine

## Key facts

- **NCT ID:** NCT00128895
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-06
- **Primary completion:** 2014-06
- **Final completion:** 2014-12
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2018-12-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00128895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00128895, "Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00128895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*